F. George Njoroge Email and Phone Number
F. George Njoroge work email
- Valid
- Valid
- Valid
- Valid
F. George Njoroge personal email
Inducted to "Hall of Fame" as a 2012 ACS Hero of chemistry for the discovery of Victrelis, the first Hepatitis C virus protease inhibitor approved by FDADirected discoveries of hepatitis C drugs Victrelis™ (BOCEPREVIR®) that was approved by FDA on May 13th 2011 as the first HCV protease inhibitor and NARLAPREVIR® a second generation HCV protease drug licensed to a Russian company, R-Phama. Spearheaded the discovery of the anti-cancer drug SARASAR®, this drug was approved on the 24th of November 2020 as Zokinvy for the treatment of progeria. Published 104 US granted patents and 136 papers in reputable journals. Received Thomas Alva Edison Patent Award for US patent work on Boceprevir®. Received Emerald Award from Career communication group for leadership excellence in drug discovery.FIRST AFRICAN TO BE GRANTED OVER 100 PATENTS BY US PATENTING AGENCYLink: http://www.mwakilishi.com/content/articles/2012/08/26/a-leading-kenyan-scientist-based-in-the-us-named-a-hero-of-chemistry.htmlSpecialties: Managed collaboration with other institutions, engaged CRO's, active in due diligence efforts, managed expence centre.
-
Chairman Of Council, Daystar UniversityDaystar University Jul 2022 - Present -
Chief Scientific Advisor, KutrrhKenyatta University Teaching Referral And Research Hospital Apr 2022 - PresentNairobi, KenyaOversee Research grants
-
Commitee Member Of Ontario Institute For Cancer Research Therapeutics Pipeline Advisory BoardOntario Institute For Cancer Research Therapeutics Jan 2021 - PresentOntario, CanadaReview of scientific research proposals submitted by Canadians in the oncology area
-
Founder And Chairman Of Center Of Africa’S Life Sciences (C.O.A.L.S)Center Of Africa’S Life Sciences (C.O.A.L.S) Jan 2019 - PresentNaivasha, Nakuru, KenyaLife Sciences including, research, drug manufacturing, scientific meetings
-
Board Director At Kemri And Chairperson Of Scientific Research And InnovationKenya Medical Research Institute(Kemri) May 2021 - Jul 2023Mbagathi, NairobiNational medical research for innovation and informing policy to Kenyan Ministry of Health
-
Board Member Of University Council, Kca UniversityKca University Jul 2020 - Jun 2023Ruaraka, Nairobi, KenyaOversight in management of university including providing directions in research activities -
Chief Scientific Advisor /Ag Director Research, Innovation & EntrepreneurshipKenyatta University Teaching, Referral And Research Hospital Aug 2020 - Aug 2022Nairobi, KenyaInnovating New Medical Modalities
-
Senior Research FellowEli Lilly And Company Aug 2011 - Dec 2019Indianapolis, Indiana AreaDrug Discovery Efforts -
Director, Medicinal ChemistryMerck Nov 2009 - Nov 2011Direct discovery of medicines in the anti-viral and related areas -
Director, Medicinal ChemistrySchering-Plough Research Institute Apr 2005 - Nov 2009• Directed a team of twenty chemists towards discovery of the second generation HCV protease inhibitor, Narlaprevir®, (SCH 900518) that is currently in Phase II clinical trials – this molecule is considered to be “the best in class”.• Directed a team of twenty chemists that discovered very potent non nucleoside HCV polymerase inhibitor - SCH 900942 – was advanced to Phase I Clinical trials. -
Associate Director, Medicinal Chemistry, Schering-Plough Research InstituteSchering-Plough Research Institute Apr 2000 - Apr 2005• Directed a team of thirteen chemists in the discovery of the first in class HCV protease inhibitor, Boceprevir® (SCH 503034) that has demonstrated remarkable efficacy in HCV viral load reduction and is currently in Phase III clinical trials.
-
Senior Principal ScientistSchering-Plough Research Institute Mar 1996 - Apr 2000• Headed a group involved in identification of a back-up compound to SARASAR®.
-
Principal ScientistSchering-Plough Research Institute Mar 1991 - Mar 1996• Led the way to the discovery of farnesyl transferase inhibitor, SARASAR® that is currently in Phase II clinical trials for the treatment of Progeria.
-
Senior ScientistSchering-Plough Research Institute Apr 1988 - Apr 1991• Designed and synthesized very potent collagenase IV inhibitors that inhibited metastasis in cancer cells.
-
Senior Research AssociateCase Western Reserve University Apr 1987 - Apr 1988• Established major agents involved in cross-linking of proteins in diabetic and aging people. This work provided important bio-markers for evaluating disease progression. -
Research AssociateCase Western Reserve University May 1985 - Mar 1987• Established the relevance of the Maillard reaction (browning) in complications associated with diabetes and aging processes
-
FellowUniversity Of Nairobi 1975 - 1980
F. George Njoroge Skills
F. George Njoroge Education Details
-
Organic Chemistry
-
Chemistry
-
Thika High School
Frequently Asked Questions about F. George Njoroge
What company does F. George Njoroge work for?
F. George Njoroge works for Daystar University
What is F. George Njoroge's role at the current company?
F. George Njoroge's current role is Founder and Chairman of Center of Africa’s Life Sciences (C.O.A.L.S).
What is F. George Njoroge's email address?
F. George Njoroge's email address is fa****@****msn.com
What schools did F. George Njoroge attend?
F. George Njoroge attended Case Western Reserve University, University Of Nairobi, Thika High School.
What skills is F. George Njoroge known for?
F. George Njoroge has skills like Medicinal Chemistry, Drug Discovery, Cro, Clinical Trials, Biomarker Discovery, Patents, Drug Design, Dmpk, Pharmaceutical Research, Adme, Drug Development, Lc Ms.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial